Business Wire1mon
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low (TPS <10) PD-L1 tumor expression.
TMCnet8d
Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification
Agilent's PD-L1 IHC 28-8 pharmDx (Code SK005) provides clinically relevant information about PD-L1 expression - a critical biomarker for potential response to therapies containing anti-PD-1 antibodies ...